On August 2, 2023, Forte Biosciences, Inc. announced that it has received shareholder proposal from ATG Capital Management LLC requesting the board of directors to amend Article VIII of the bylaws to add the new Section 41 Stockholder Rights Plans and to renumber the remaining sections accordingly:1) Rights Plans. Notwithstanding anything in these Bylaws to the contrary, the adoption or amendment of any Stockholder Rights Plan which has the effect of extending the term of the Stockholder Rights Plan or any rights or options provided thereunder shall not be effective unless ratified by the stockholders; 2) Definition. The term Stockholder Rights Plan in this Section 41 refers to any stockholder rights plan, stockholder rights agreement or any other form of ?poison pill?

anti-takeover device, plan or agreement that is designed to or has the effect of making an acquisition of large holdings of the corporation?s shares of stock more difficult or expensive (but for the avoidance of doubt, excluding any issuance or sale of securities or rights in connection with a bona fide financing transaction); 3) State Law. Nothing in this Section 41 should be construed to permit or validate any decision by the Board of Directors to adopt or amend a Stockholder Rights Agreement that would otherwise be prohibited or invalid under applicable Delaware law. Further, Forte Biosciences, Inc stated that the board recommended shareholders to vote against the shareholder proposal at the annual meeting of shareholders to be held on September 19, 2023.